We read with interest the letter by Fukuda and Miura,^[@bib1]^ in response to our article. As they commented, the degree of sodium intake is known to significantly affect the effectiveness of angiotensin II receptor blockers (ARBs) in patients with chronic kidney disease. However, in the OSCAR study, we did not monitor urinary sodium levels and therefore, the role of salt sensitivity in the OSCAR study is unclear. Furthermore, it is unknown whether the elderly patients enrolled in the OSCAR study exhibited glomerular hypertension or not. Unfortunately, measurement of urinary protein or albumin was not performed in the OSCAR study. However, 680 patients of 1164 enrolled patients had urinary protein test by dipstick analysis at baseline. According to the request, we present the subgroup analysis data according to the presence or absence of proteinuria at baseline ([Figure 1](#fig1){ref-type="fig"}). In patients with urinary protein +1 or greater, more primary events (a composite of cardiovascular events and non-cardiovascular death) occurred in the high-dose ARB group than in the ARB + calcium channel blocker (CCB) group (15 vs 5 events, hazard ratio (HR), 3.31, 95% confidence interval (CI) 1.12--9.8; *P*=0.0254). On the other hand, in patients with urinary protein -- or ±, the incidence of primary events was similar between the two treatments (HR=1.13, 95% CI 0.61--2.09; *P*=0.7034). Thus, our subanalysis suggests that ARB+CCB combination, compared to high-dose ARB, conferred greater benefit in prevention of cardiovascular events in patients with proteinuria, being consistent with the findings^[@bib2]^ on patients with estimated glomerular filtration rate of \<60 ml/min per 1.73 m^2^. The superiority of ARB+CCB combination might be at least in part attributed to the potential improvement of renal blood flow through arterial vasodilation, because the elderly patients are characterized by significant vascular stiffness. However, further clinical study is required to define our proposal, as the number of patients in the OSCAR study is limited.

![**Kaplan--Meier curves.** For primary composite end points during the follow-up period in patients (**a**) with and (**b**) without proteinuria. ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CI, confidence interval; HR, hazard ratio.](ki2013313f1){#fig1}
